Sun Pharma has suffered a gut-wrenching drop in its sales in the U.S. as ongoing regulatory restraints for Sun Pharma’s key API plant in India, along with generic pricing pressures, did a number on the drugmaker’s final quarter.
India’s Sun Pharmaceutical has had its ambitions stymied by FDA action against a key manufacturing plant, but it still managed to generate more than $3.6 billion in generic sales last year.
